CIS Launches Emergent BioPharma Insights™ With An Executive Symposium On The West Coast

Compliance Implementation Services (CIS) today announced it will host an executive breakfast symposium, "Know Your Options: Considering a "Virtual" Commercial Operation," as a part of its Emergent BioPharma Insights™ compliance series tailo

Compliance Implementation Services (CIS), a leading life sciences consulting firm, today announced it will host an executive breakfast symposium, "Know Your Options: Considering a "Virtual" Commercial Operation," as a part of its Emergent BioPharma Insights™ compliance series tailored for emerging biopharma companies.

On February 12, a panel of industry experts from CIS, D2 Pharma Consulting, and Dendreon will discuss the options available to emerging companies considering commercial operations.

"Since launching a product is one of the most critical times for emerging companies, and the makings of a successful launch start years before the product hits the market, executives must systematically develop plans to maximize commercial viability and ensure that logistics are coordinated and expertly managed," said Chris Cobourn, Senior Vice President, Commercial Compliance at CIS.

"During the symposium we will discuss a timeline that introduces the specific components of the virtual commercialization model as it relates to supply chain management, compliance programs, contract management, and government programs participation. Attendees will learn key insights and best practices from companies who successfully implemented this model."

Emerging biopharma companies have determined that a large pharma partner is not necessarily required to successfully launch a product in the US market. These companies are seeing an opportunity to retain control over the products they have worked so hard to develop by pursuing their own commercialization strategies in the form of a serviced-based, outsourced model.

This "virtual" commercialization model minimizes internal systems and staffing while utilizing best-in-class operational support at each stage of pre-launch commercial planning.

Key topics to be covered during the discussion include:

• What are the key operational components of outsourced commercialization and back office support?

• How do you determine which activities are relevant to your business and the timeline for implementation?

• What are the compliance considerations and the options to avoid unknown risks?

• Why is the US government market important?

Cobourn adds, "Planning and preparing for commercialization may seem light years away, but now is the time to start thinking about important commercial relationships, contracting strategies, regulatory hurdles, and the various Federal and State compliance and reporting requirements that could have a major impact on your commercial success. To help manufacturers make sense of it all, this symposium brings in industry veterans to discuss best practices and new approaches for bringing products to market."


Categories: Small Business

Tags: BayBio, Chris Cobourn, cis, Emergent BioPharma Insightsâ„¢


About Compliance Implementation Services

View Website

Christine Pahl
Compliance Implementation Services
Compliance Implementation Services
3809 West Chester Pike, Newtown Square, PA
Suite 100
19073
United States